Fluorescent in situ hybridization in the diagnosis, prognosis, and treatment monitoring of chronic myeloid leukemia

References

• Tefferi A M, Dewald G WP, Litzow M LM, Cortes J M, Mauro M JM, Talpaz M M, et al. Chronic myeloid leukemia: current application of cytogenetics and molecular testing for diagnosis and treatment. Mayo Clinic Proc 2005; 80: 390–402
   PubMed Web of Science ®Google Scholar
• Nowell P, Hungerford D. A minute chromosome in human chronic granulocytic leukemia. Science 1960; 132: 1497–1501
   Web of Science ®Google Scholar
• Goldman J. Monitoring minimal residual disease in BCR-ABL-positive chronic myeloid leukemia in the imatinib era. Curr Opin Hematol 2005; 12: 33–39
   PubMed Web of Science ®Google Scholar
• Dewald G W, Juneau A L, Schad C R, Tefferi A. Cytogenetic and molecular genetic methods for diagnosis and treatment response in chronic granulocytic leukemia. Cancer Genet Cytogenet 1997; 94: 59–66
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, Faderl S, O'Brien S, Cortes J, Talpaz M, et al. Chronic myelogenous leukemia: a review and update of therapeutic strategies. Cancer 2003; 98: 437–457
   PubMed Web of Science ®Google Scholar
• Kantarjian H M, Keating M J, Talpaz M, Walters R S, Smith T L, Cork A, et al. Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients. Am J Med 1987; 83: 445–454
   PubMed Web of Science ®Google Scholar
• Chase A, Huntly B JP, Cross N CP. Cytogenetics of chronic myeloid leukaemia. Best Pract Res Clin Haematol 2001; 14: 553–571
   PubMed Web of Science ®Google Scholar
• Sokal J, Baccarani M, Russo D, Tura S. Staging and prognosis in chronic myelogenous leukemia. Semin Hematol 1988; 25: 49–61
   PubMed Web of Science ®Google Scholar
• Schiffer C A, Hehlmann R, Larson R. Perspectives on the treatment of chronic phase and advanced phase CML and Philadelphia chromosome positive ALL. Leukemia 2003; 17: 691–699
   PubMed Web of Science ®Google Scholar
• Cortes J, Kantarjian H. Advanced-phase chronic myeloid leukemia. Semin Hematol 2003; 40: 79–86
   PubMed Web of Science ®Google Scholar
• Calabretta B, Perrotti D. The biology of CML blast crisis. Blood 2004; 103: 4010–4022
   PubMed Web of Science ®Google Scholar
• Cortes J E, O'Brien S M, Giles F, Alvarez R H, Talpaz M, Kantarjian H M. Investigational strategies in chronic myelogenous leukemia. Hematol Oncol Clin North Am 2004; 18: 619–639
   PubMed Web of Science ®Google Scholar
• Goldman J M, Melo J V. Chronic myeloid leukemia–advances in biology and new approaches to treatment. N Engl J Med 2003; 349: 1451–1464
   PubMed Web of Science ®Google Scholar
• Rowley J D. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973; 243: 290–293
   PubMed Web of Science ®Google Scholar
• Fialkow P J, Gartler S M, Yoshida A. Clonal origin of chronic myelocytic leukemia in man. Proc Natl Acad Sci USA 1967; 58: 1468–1471
   PubMed Web of Science ®Google Scholar
• de Klein A, van Kessel A G, Grosveld G, Bartram C R, Hagemeijer A, Bootsma D, et al. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature 1982; 300: 765–767
   PubMed Web of Science ®Google Scholar
• Heisterkamp N, Stam K, Groffen J, de Klein A, Grosveld G. Structural organization of the bcr gene and its role in the Ph’ translocation. Nature 1985; 315: 758–761
   PubMed Web of Science ®Google Scholar
• Stam K, Heisterkamp N, Grosveld G, de Klein A, Verma R S, Coleman M, et al. Evidence of a new chimeric bcr/c-abl mRNA in patients with chronic myelocytic leukemia and the Philadelphia chromosome. N Engl J Med 1985; 313: 1429–1433
   PubMed Web of Science ®Google Scholar
• Ben-Neriah Y, Daley G Q, Mes-Masson A M, Witte O N, Baltimore D. The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. Science 1986; 233: 212–214
   PubMed Web of Science ®Google Scholar
• Lugo T G, Pendergast A M, Muller A J, Witte O N. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990; 247: 1079–1082
   PubMed Web of Science ®Google Scholar
• Kelliher M A, McLaughlin J, Witte O N, Rosenberg N. Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL. Proc Natl Acad Sci USA 1990; 87: 6649–6653
   PubMed Web of Science ®Google Scholar
• Daley G Q, Van Etten R A, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990; 247: 824–830
   PubMed Web of Science ®Google Scholar
• Sattler M, Salgia R, Okuda K, Uemura N, Durstin M A, Pisick E, et al. The proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR/ABL and p210BCR/ABL to the phosphatidylinositol-3′ kinase pathway. Oncogene 1996; 12: 839–846
   PubMed Web of Science ®Google Scholar
• Lesser M L, Dewald G W, Sison C P, Silver R T. Correlation of three methods of measuring cytogenetic response in chronic myelocytic leukemia. Cancer Genet Cytogenet 2002; 137: 79–84
   PubMed Web of Science ®Google Scholar
• Buno I, Wyatt W A, Zinsmeister A R, Dietz-Band J, Silver R T, Dewald G W. A special fluorescent in situ hybridization technique to study peripheral blood and assess the effectiveness of interferon therapy in chronic myeloid leukemia. Blood 1998; 92: 2315–2321
   PubMed Web of Science ®Google Scholar
• Sinclair P B, Green A R, Grace C, Nacheva E P. Improved sensitivity of BCR-ABL detection: a triple-probe three-color fluorescence in situ hybridization system. Blood 1997; 90: 1395–1402
   PubMed Web of Science ®Google Scholar
• Cuneo A, Bigoni R, Emmanuel B, Smit E, Rigolin G, Roberti M, et al. Fluorescence in situ hybridization for the detection and monitoring of the Ph-positive clone in chronic myelogenous leukemia: comparison with metaphase banding analysis. Leukemia 1998; 12: 1718–1723
   PubMed Web of Science ®Google Scholar
• Cox-Froncillo M C, Cantonetti M, Masi M, Lentini R, Giudiceandrea P, Maffei L, et al. Cytogenetic analysis is non-informative for assessing the remission rate in chronic myeloid leukemia (CML) patients on interferon-alpha (IFN-alpha) therapy. Cancer Genet Cytogenet 1995; 84: 15–18
   PubMed Web of Science ®Google Scholar
• Tkachuk D, Westbrook C, Donlon T, Cleary M, Suryanarayan K, Homge M, et al. Detection of bcr-abl fusion in chronic myelogeneous leukemia by in situ hybridization. Science 1990; 250: 559–562
   PubMed Web of Science ®Google Scholar
• Dewald G W, Schad C R, Christensen E R, Tiede A L, Zinsmeister A R, Spurbeck J L, et al. The application of fluorescent in situ hybridization to detect Mbcr/abl fusion in variant Ph chromosomes in CML and ALL. Cancer Genet Cytogenet 1993; 71: 7–14
   PubMed Web of Science ®Google Scholar
• Chase A, Grand F, Zhang J -G, Blackett N, Goldman J, Gordon M. Factors influencing the false positive and negative rates of BCR-ABL fluorescence in situ hybridization. Genes Chrom Cancer 1997; 18: 246–253
   PubMed Web of Science ®Google Scholar
• Dewald G W, Wyatt W A, Juneau A L, Carlson R O, Zinsmeister A R, Jalal S M, et al. Highly sensitive fluorescence in situ hybridization method to detect double BCR/ABL fusion and monitor response to therapy in chronic myeloid leukemia. Blood 1998; 91: 3357–3365
   PubMed Web of Science ®Google Scholar
• Seong D, Kantarjian H, Ro J, Talpaz M, Xu J, Robinson J, et al. Hypermetaphase fluorescence in situ hybridization for quantitative monitoring of Philadelphia chromosome-positive cells in patients with chronic myelogenous leukemia during treatment. Blood 1995; 86: 2343–2349
   PubMed Web of Science ®Google Scholar
• Amare P S, Baisane C, Saikia T, Nair R, Gawade H, Advani S. Fluorescence in situ hybridization: a highly efficient technique of molecular diagnosis and predication for disease course in patients with myeloid leukemias. Cancer Genet Cytogenet 2001; 131: 125–134
   PubMed Web of Science ®Google Scholar
• Kantarjian H M, Bueso-Ramos C E, Talpaz M, O'Brien S, Giles F, Faderl S, et al. Significance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapy. Cancer 2005; 104: 777–780
   PubMed Web of Science ®Google Scholar
• Kantarjian H M, Bueso-Ramos C E, Talpaz M, O'Brien S, Giles F, Rios M B, et al. The degree of bone marrow fibrosis in chronic myelogenous leukemia is not a prognostic factor with imatinib mesylate therapy. Leuk Lymphoma 2005; 46: 993–997
   PubMed Web of Science ®Google Scholar
• Vardiman J W, Brunning R D, Harris N L. WHO histological classification of chronic myeloproliferative diseases. World Health Organization Classification of Tumors: Tumors of the Haematopoietic and Lymphoid Tissues, E S Jaffe, N L Harris, H Stein, J W Vardiman. International Agency for Research on Cancer (IARC) Press, Lyon 2001
   Google Scholar
• Hasford J, Pfirrmann M, Hehlmann R, Baccarani M, Guilhot F, Mahon F X, et al. Prognosis and prognostic factors for patients with chronic myeloid leukemia: nontransplant therapy. Semin Hematol 2003; 40: 4–12
   PubMed Web of Science ®Google Scholar
• Sokal J E, Cox E B, Baccarani M, Tura S, Gomez G A, Robertson J E, et al. Prognostic discrimination in ‘good-risk’ chronic granulocytic leukemia. Blood 1984; 63: 789–799
   PubMed Web of Science ®Google Scholar
• Hasford J, Pfirrmann M, Hehlmann R, Allan N C, Baccarani M, Kluin-Nelemans J C, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 1998; 90: 850–858
   PubMed Web of Science ®Google Scholar
• Sokal J E, Gomez G A, Baccarani M, Tura S, Clarkson B D, Cervantes F, et al. Prognostic significance of additional cytogenetic abnormalities at diagnosis of Philadelphia chromosome-positive chronic granulocytic leukemia. Blood 1988; 72: 294–298
   PubMed Web of Science ®Google Scholar
• Werner M, Kaloutsi V, Buhr T, Delventhal S, Vykoupil K F, Georgii A. Cytogenetics of chronic myelogenous leukemia (CML) correlated to the histopathology of bone marrow biopsies. Ann Hematol 1991; 63: 201–205
   PubMed Web of Science ®Google Scholar
• Lundan T, Volin L, Ruutu T, Knuutila S, Porkka K. Allogeneic stem cell transplantation reverses the poor prognosis of CML patients with deletions in derivative chromosome 9. Leukemia 2005; 19: 138–140
   PubMed Web of Science ®Google Scholar
• Sinclair P B, Nacheva E P, Leversha M, Telford N, Chang J, Reid A, et al. Large deletions at the t(9;22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia. Blood 2000; 95: 738–743
   PubMed Web of Science ®Google Scholar
• Huntly B JP, Reid A G, Bench A J, Campbell L J, Telford N, Shepherd P, et al. Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia. Blood 2001; 98: 1732–1738
   PubMed Web of Science ®Google Scholar
• Huntly B JP, Bench A J, Delabesse E, Reid A G, Li J, Scott M A, et al. Derivative chromosome 9 deletions in chronic myeloid leukemia: poor prognosis is not associated with loss of ABL-BCR expression, elevated BCR-ABL levels, or karyotypic instability. Blood 2002; 99: 4547–4553
   PubMed Web of Science ®Google Scholar
• Specchia G, Albano F, Anelli L, Storlazzi C T, Zagaria A, Liso A, et al. Derivative chromosome 9 deletions in chronic myeloid leukemia are associated with loss of tumor suppressor genes. Leuk Lymphoma 2004; 45: 689–694
   PubMed Web of Science ®Google Scholar
• Kolomietz E, Al-Maghrabi J, Brennan S, Karaskova J, Minkin S, Lipton J, et al. Primary chromosomal rearrangements of leukemia are frequently accompanied by extensive submicroscopic deletions and may lead to altered prognosis. Blood 2001; 97: 3581–3588
   PubMed Web of Science ®Google Scholar
• Storlazzi C T, Specchia G, Anelli L, Albano F, Pastore D, Zagaria A, et al. Breakpoint characterization of der(9) deletions in chronic myeloid leukemia patients. Genes Chrom Cancer 2002; 35: 271–276
   PubMed Web of Science ®Google Scholar
• Cohen N, Rozenfeld-Granot G, Hardan I, Brok-Simoni F, Amariglio N, Rechavi G, et al. Subgroup of patients with Philadelphia-positive chronic myelogenous leukemia characterized by a deletion of 9q proximal to ABL gene: expression profiling, resistance to interferon therapy, and poor prognosis. Cancer Genet Cytogenet 2001; 128: 114–119
   PubMed Web of Science ®Google Scholar
• Yoong Y, Van DeWalker T J, Carlson R O, Dewald G W, Tefferi A. Clinical correlates of submicroscopic deletions involving the ABL-BCR translocation region in chronic myeloid leukemia. Eur J Haematol 2005; 74: 124–127
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Kantarjian H, Talpaz M, O'Brien S, Garcia-Manero G, Verstovsek S, et al. Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia. Blood 2005; 105: 2281–2286
   PubMed Web of Science ®Google Scholar
• Frater J, Tallman M, Variakojis D, Druker B, Resta D, Riley M, et al. Chronic myeloid leukemia following therapy with imatinib mesylate (Gleevec). Bone marrow histopathology and correlation with genetic status. Am J Clin Pathol 2003; 119: 833–841
   PubMed Web of Science ®Google Scholar
• Tchirkov A, Giollant M, Tavernier F, BrianCon G, Tournilhac O, Kwiatkowski F, et al. Interphase cytogenetics and competitive RT-PCR for residual disease monitoring in patients with chronic myeloid leukaemia during interferon- therapy. Br J Haematol 1998; 101: 552–557
   PubMed Web of Science ®Google Scholar
• Douet-Guilbert N, Morel F, Le Charpentier T, Le Bris M J, Herry A, Morice P, et al. Interphase FISH for follow-up of Philadelphia chromosome-positive chronic myeloid leukemia treatment. Anticancer Res 2004; 24: 2535–2539
   PubMed Web of Science ®Google Scholar
• Muhlmann J, Thaler J, Hilbe W, Bechter O, Erdel M, Utermann G, et al. Fluorescence in situ hybridization (FISH) on peripheral blood smears for monitoring Philadelphia chromosome-positive chronic myeloid leukemia (CML) during interferon treatment: a new strategy for remission assessment. Genes Chrom Cancer 1998; 21: 90–100
   PubMed Web of Science ®Google Scholar
• Bornhauser M, Mohr B, Ehrenlechner U, Neubauer A, Ehninger G. Fluorescence in situ hybridization for the BCR/ABL rearrangement is dependent on the percentage of nonlymphocytic cells in peripheral blood stem cell harvests. J Hematother 1998; 7: 425–430
   PubMedGoogle Scholar
• Kim Y J, Kim D W, Lee S, Kim H J, Kim Y L, Hwang J Y, et al. Comprehensive comparison of FISH, RT-PCR, and RQ-PCR for monitoring the BCR-ABL gene after hematopoietic stem cell transplantation in CML. Eur J Haematol 2002; 68: 272–280
   PubMed Web of Science ®Google Scholar
• Raanani P, Ben-Bassat I, Gan S, Trakhtenbrot L, Mark Z, Ashur-Fabian O, et al. Assessment of the response to imatinib in chronic myeloid leukemia patients – comparison between the FISH, multiplex and RT-PCR methods. Eur J Haematol 2004; 73: 243–250
   PubMed Web of Science ®Google Scholar
• Kantarjian H M, Talpaz M, Cortes J, O'Brien S, Faderl S, Thomas D, et al. Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia. Clin Cancer Res 2003; 9: 160–166
   PubMed Web of Science ®Google Scholar
• Radich J P, Gehly G, Gooley T, Bryant E, Clift R A, Collins S, et al. Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients. Blood 1995; 85: 2632–2638
   PubMed Web of Science ®Google Scholar
• Lin F, Goldman J M, Cross N C. A comparison of the sensitivity of blood and bone marrow for the detection of minimal residual disease in chronic myeloid leukaemia. Br J Haematol 1994; 86: 683–685
   PubMed Web of Science ®Google Scholar
• Branford S, Hughes T P, Rudzki Z. Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics. Br J Haematol 1999; 107: 587–599
   PubMed Web of Science ®Google Scholar
• Hughes T P, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley M L, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003; 349: 1423–1432
   PubMed Web of Science ®Google Scholar
• Dewald G W, Wyatt W A, Juneau A L, Carlson R O, Zinsmeister A R, Jalal S M, et al. Highly sensitive fluorescence in situ hybridization method to detect double BCR/ABL fusion and monitor response to therapy in chronic myeloid leukemia. Blood 1998; 91: 3357–3365
   PubMed Web of Science ®Google Scholar